Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus by Kawanishi,Koichi et al.
Acta Medica Okayama
Volume 31, Issue 5 1977 Article 4
OCTOBER 1977
Decreased plasma postheparin lipolytic
activity in systemic lupus erythematosus
Koichi Kawanishi Hidenori Ueday
Masayuki Nagasez Tadashi Ofuji
Okayama University,
yOkayama University,
zOkayama University,
Okayama University,
Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.Decreased plasma postheparin lipolytic
activity in systemic lupus erythematosus
Koichi Kawanishi, Hidenori Ueda, Masayuki Nagase, and Tadashi Ofuji
Abstract
Plasma postheparin lipolytic activity (PHLA) was measured on 50 patients with systemic
lupus erythematosus (SLE). Plasma PHLA was signiﬁcantly decreased in SLE patients. This
decrease was most striking in the acute phase of the disease. There was a close relationship
between decreased PHLA and immunologic factors indicative of the acute phase of SLE. These
immunologic factors included shaggy antinuclear antibody pattern, low serum complement titer,
high DNA antibody titer, mixed cryoglobulin and lumpy glomerular pattern by immunoﬂuorescent
staining.
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Abstract. Plasma postheparin lipolytic activity (PHLA) was mea-
sured on50 patients with systemic lupus erythematosus (SLE). Plasma
PHLA was significantly decreased in SLE patients. This decrease
was most striking in the acute phase of the disease. There was a close
relationship between decreased PHLA and immunologic factors indi-
cative of the acute phase ofSLE. These immunologicfactors included
shaggy antinuclear antibody pattern, low serum complement titer,
high DNA antibody titer, mixed cryoglobulin and lumpy glomerular
pattern by immunofluorescent staining.
Hyperlipoproteinemia may be present invarious collagen diseases (1). Type
1 and type 3 hyperlipoproteinemias combined with decreased postheparin lipoly-
tic activity (PHLA) have been reported in a few cases ofsystemic lupuserythe-
matosus (SLE) (2-4). In a previous study of 67 SLE patients, we found that
about 40% of patients had type 2a hyperlipoproteinemia and 40% had type 4
hyperlipoproteinemia (5). In the presentstudy, plasmaPHLA and some selected
immunological measures were studied in a group ofSLE patients.
MATERIALS AND METHODS
A total of 50 consecutive hospitalized SLE patientswas examined (5 males,
45 females; aged 12-51). The criteria ofSLE diagnosiswere according toCohen
et al, (6). A few patients were examined during both the acute and remission
periods, as defined by Schur and Sandson (7). The diagnoses were made by
one author (H.D.) independent of the PHLA values. All patients were being
treated with steroids. Most patients in the acute phase were receiving a daily
dose of 30mg of prednisolone, and most patients in remission were receiving
a daily dose of lOmg of prednisolone. Other immunosuppressive agents used
together with prednisolone were: cyclophosphamide (lOOmg/day in acute
phase and 5Omg/day in remission, 11 patients); azathioprin (lOOmg/day in
acute phase and 50mg/day in remission, 7 patients); and 6-mercaptopurine
(50mg/day in acute phase and 25mg/day in remission, 5 patients). Thirty, non-
obese hospital staff members served as control subjects (15 males, 15 females;
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aged 20-40). None of the control subjects had plasma lipid abnormalities. In
SLE patients, blood samples were obtained 10, 20 and 30min after an intra-
venous injection of heparin sodium at O. I mg/kg of body weight. In normal
controls, blood samples were obtained at the same time periods after the same
dose of heparin injection as the patients.
Plasma PHLA was determined by a slight modification of the technique of
Fredrickson et al. (8). Glass-stoppered tubes containing a.5ml of 5% bovine
albumin (Fraction V), 5mg of coconut oil emulsion (Ediol), a.2ml of ammo-
nium chloride and O.2ml of plasma in a total volume of l.Oml were incubated
at 37°C for 30min. Free fatty acid (FFA) concentrations in O.2ml of the sub-
strate-plasma mixture were determined by the method of Itaya and Ui (9).
PHLA was calculated from the difference in FFA concentration between the
incubated tube and control tube. The values were expressed as pEqFFA/ml,
min plasma.
Results were obtained from most patients for each of the following: anti-
nuclear antibodies (ANA) separated into shaggy, diffuse and speckled patterns
(10, 11); serum complement titer (CH50) (12); DNA antibody titer (13); cryo-
globulin of IgG and IgG-IgM mixed type (15); and immunofluorescent staining
of biopsied kidney differentiated into linear, mesangial, granular or lumpy
patterns of glomeruli (16). In biopsied patients plasma PHLA values were
determined no later than 2 weeks after biopsy. Histologic examinations were
conducted on biopsied specimens stained by hematoxylin-eosin.
RESULTS
Mean plasma PHLA values (,.uEqFFA/mljmin) of normal subjects were
0.249 at 10 min; 0.192 at 20 min; and 0.039 at 30 min. There were no differ-
ences between the sexes in the result for the control plasma PHLA. SLE plasma
PHLA was significantly 10 ,er compared to normal subjects (Fig. 1). The SLE
patient response was prominent in the acute phase of the disease. The mean
acute patient values v.ere 0.05'0 at lOmin; 0.0)7 at 20 min, and 0.019 at SO min.
PHLA values in remission were 0.111 at 10 min; 0.070 at 20 min; and 0.040 at
20 min, There were no differences between the sexes in the results for the
plasma PHLA of SLE patients PHLA values were not related to the type of
immunosuppressive agents used in treatment.
Patients with the shaggy ANA pattern showed significantly lower plasma
PHLA compared with patients with diffuse or speckled patterns (Table 1). A
positive correlation was prfs~nt between PHLA and serum compl'ment titer
(Fig. 2). The DNA antibody titer showed an inverse correlation with PHLA
(Fig. 3). Patients with positive cryoglobulin showed lower plasma PHLA values
than patients with negative cryoglobulin; patients with IgG-IgM mixed cryo-
globulin showed decreased plasma PHLA values compared with IgG type cryo-
globulin (Table 1). Patients with lumpy immunofluorescent patterns showed a
2
Acta Medica Okayama, Vol. 31 [1977], Iss. 5, Art. 4
http://escholarship.lib.okayama-u.ac.jp/amo/vol31/iss5/4Postheparin Lipoiytic Activity in SLE 321
D NORMAL RANGE 1M ± so
rO · ·
rO · ·
r
: .. . ...
rD IJ:
... r
I .
:i: · · .. :r
.. .
I'3' j~ I ... .. .. ... .. r;fj;
... ... · ·:r· ... ... .
ACUTE PHASEI REMISSION ACUTE PHASE I REM 15SI0N ACUTE PHASEI REMISSION
10 min 20 min 30 min
0.100
0.200
}JEqFFA/ml/min
0.300
Fig. 1. Plasma PHLA levels at three time periods after heparin administration
(0.1 mg/kg) in the acute and remission periods of SLE patients. Plasma PHLA was
significantly lower in SLE patients compared to the control values (P<.OOl at 10, 20
and 30min). Plasma PHLA levels during the acute phase were depressed compared
to PHLA levels during remission (P<.Ol at 10, 20 and 30 min).
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Fig. 2. Relationship between plasma PHLA 10 min after heparin administra-
tion and serum complement titer in SLE patients. Plasma PHLA level correlated
positively with serum complement titer (r=0.485).
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Fig. 3. Relationship between plasma PHLA 10 min after heparin administra-
tion and DNA antibody titer in SLE patients. Plasma PHLA level correlated in-
versely with DNA antibody titer Ir = -- 0.445).
TABLE 1. RELATIONSHIPS BETWEEN IMMl'NOLOGIC MEASURES AND PLASMA PHLA
LEVELS l,uEQFFA/ML/MINI IN SLE PATIENTS
Antinuclear
antibodies
(number of
patients)
PHLA (Mean ± SD)
10 min
after heparin
injection
Cryoglobulin
(number of
patients)
PHLA (Mean ± SD)
10 min
after heparin
injection
Immunofluorescent
patterns of
glomeruli
(number of
patients)
PHLA (Mean
10 min
after heparin
injection
Shaggy (23)
0.058 ± 0.029*
IgG-IgM (81
0.060 0.022
C
Lumpy (4)
0.042 0.013""
Diffuse (21)
0.0~5 ::J= 0.044
IgG (13)
0.095 ± 0.037
Granular (14)
0.073 +: 0.029
Speckled Ill)
0.131 ± 0.066
Negative (5)
0.116 =!-: 0.033
Mesangial and
linear (12)
0.110 ± 0.035
---------------------------
* P < .05 with diffuse pattern; p .01 with speckled pattern
+ P < .05 with IgG; P < .01 with negative cryoglobulin
P < .01 with mesangial and with linear immunflouorescent patterns
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significant PHLA depression compared to patients with mesangial or linear im-
munofluorescent patterns (Table I). Most patients with mesangial and linear
patterns showed normal or minimal histological changes in the glomeruli. Pa-
tients with granular patterns showed focal or diffuse proliferative glomerulone-
phritis and membranous glomerulonephritis. Most cases with lumpy patterns
showed membranous glomerulonephritis including wire-lOOp lesions.
DISCUSSION
Several distinctive immunologic features have been reported in the acute
phase of SLE. These include shaggy ANA pattern (11), low complement levels
(7), high DNA antibody titers (14), the presence of mixC'J (IgG-IgM) cryoglo-
bulin (15), an
r1a lumpy immunofluorescent pattern of biopsied glomeruli (16).
In the present study, plasma PHLA was measured on 50 patients with SLE.
Plasma PHLA was significantly decreased inSLE patients and most strikingly in
the acute phase of the disease. A close relationship was present between (e-
creased PHLA and immunologic factors indicative of the acute phase of SLE.
Glueck et at. (2,3) reported SLE accompanied by acquired type I hyperlipo-
proteinemia, dysglobulinemia and heparin resistance in three patients. In these
cases a decrease was found in plasma PHLA, triglyceride lipase and monoglyce-
ride hydrolase. These investigators demonstrated that the plasma PHLA de-
pression was due to the association of the heparin-binding immunoglobulin with
exogenous hyperlipoproteinemia. Beaumont and Lemort (17) also reported im-
munoglobulins with antiheparin activity. Stern et al. (4) reported acquired type
3 hyperlipoproteinemia in two patients with SLE. PHLA was decreased in both
patients. In one of these patients after adrenocortical steroid treatment, the
PHLA value returned to normal concomitantly with the disappearance of the
type 3 hyperlipoproteinemia. In a previous study in our laboratory (5), SLE
patients with decreased PHLA often showed elevated plasma triglyceride. The
pathophysiology of SLE is extremely complicated, and various factors are likely
to be involved in the SLE lipid metabolism. The decreased PHLA is probably
related not only to heparin binding with serum but to other factors of immuno-
logic, metabolic and therapeutic consequence.
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